<DOC>
	<DOCNO>NCT01366651</DOCNO>
	<brief_summary>The purpose study characterize penetration doripenem cerebral spinal fluid pediatric patient &lt; 1 year age hospitalize document suspected infection planning , undergo treatment intravenous ( IV ) antibiotic .</brief_summary>
	<brief_title>A Study Doripenem CerebrospinalFluid After Doripenem Administration Pediatric Patients Less Than 1 Year Age</brief_title>
	<detailed_description>This multicenter , open-label ( identity treatment know patient 's parent/legal guardian/caregiver study staff ) study characterize penetration doripenem cerebral spinal fluid ( CSF ) pediatric patient &lt; 1 year age hospitalize medically stable , document suspected infection planning , undergo treatment antibiotic administer intravenously ( vein , abbreviate `` IV '' ) . Doripenem replace patient ' prescribe antibiotic ( ) . The study include 3 phase : pretreatment phase consist 24-hour screening period ; 2-day open-label treatment period doripenem administer , CSF blood sample collect , follow-up visit approximately 1 week administration last dose doripenem . The total duration study approximately 10 day . During study , patient &lt; 12 week age receive 10 mg/kg doripenem 1-hour IV infusion via central peripheral venous line ( catheter insert large vein ) every 8 hour ; patient 12 week &lt; 1 year age receive 30 mg/kg doripenem 1-hour IV infusion every 8 hour . A total 5 dos doripenem administer 2-day period patient hospital .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<criteria>Patient expect require hospitalization entire openlabel phase study . Patient must schedule cerebral spinal fluid obtain via lumbar puncture ( refer `` spinal tap '' ) ventriculoperitoneal ( VP ) shunt tap within 3 day enrollment study . Patient must document suspected infection planning , undergo treatment IV antibiotic . Parent patient 's legally acceptable representative must sign informed consent document indicate understand purpose procedure require study willing allow infant participate study . Clinically significant abnormal value hematology clinical chemistry screening , option investigator , consistent patient 's underlying disease ( ) therapy . Any condition screening , opinion investigator , may interfere assessment study . Patients substantially compromise renal ( kidney ) function : e.g. , urine output &lt; 0.25cc/kg/hr within 24 hour screen . History clinically significant allergy medication , especially know hypersensitivity intolerance carbapenems , penicillin , Betalactam antibiotic . Known allergy heparin history heparininduced thrombocytopenia , indwell cannula ( e.g. , heparin lock ) central line use . Patients concomitantly treat received imipenem/cilastin within 48 hour study drug administration . Patients concomitantly treat probenecid valproic acid ( VPA ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Doripenem</keyword>
	<keyword>DORIPED1002</keyword>
	<keyword>Intravenous</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Antibiotic</keyword>
	<keyword>Meningitis</keyword>
</DOC>